Request Demo
Last update 12 Mar 2026
Insulin Degludec biosimilar (Huisheng Biological)
Last update 12 Mar 2026
Overview
Basic Info
Drug Type Biosimilar, Peptide Hormone |
Synonyms Insulin degludec Biosimilar (Jilin Huisheng Biological Pharmaceutical Co., Ltd.), 德谷胰岛素生物类似药（Jilin Huisheng Biological Pharmaceutical Co., Ltd.）, 惠优达 + [1] |
Target |
Action agonists |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date China (05 Aug 2024), |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 4857
The sequence is quoted from: *****
Sequence Code 91440
The sequence is quoted from: *****
Related
5
Clinical Trials associated with Insulin Degludec biosimilar (Huisheng Biological)ChiCTR2400083084
Pharmacokinetics and Safety of Insulin Degludec/Insulin Aspart Injection with the Ryzodeg Produced by Novo Nordisk in Healthy Chinese Subjects: A phase I, Randomized, Open-label, Single-dose, Two-phase, Crossover study
ChiCTR2400081416
Efficacy and Safety of Insulin Degludec/Insulin Aspart Injection in Chinese Patients with Type 2 Diabetes: A Multicenter, Randomized, Open-label, Parallel-group, Positive-controlled, Phase 3 Study
CTR20202005
德谷胰岛素注射液治疗2型糖尿病的有效性和安全性的多中心、随机、开放、平行组、阳性对照的III期研究
[Translation] A multicenter, randomized, open, parallel-group, positive-controlled phase III study on the efficacy and safety of degludec insulin injection in the treatment of type 2 diabetes
100 Clinical Results associated with Insulin Degludec biosimilar (Huisheng Biological)
Login to view more data
100 Translational Medicine associated with Insulin Degludec biosimilar (Huisheng Biological)
Login to view more data
100 Patents (Medical) associated with Insulin Degludec biosimilar (Huisheng Biological)
Login to view more data
100 Deals associated with Insulin Degludec biosimilar (Huisheng Biological)
Login to view more data
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Diabetes Mellitus, Type 2 | China | 05 Aug 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free